HC Wainwright Rates Humacyte (HUMA) buy, $4 Price Target

HC Wainwright maintains a buy rating for Humacyte, setting a $4.00 price target, a 288.35% upside from the current price.

By EarningsIQ Research Desk · Published Jun 12, 2026, 9:12 PM EDT · Updated Jun 17, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Humacyte, Inc. ($HUMA) "buy" with a $4 price target on June 11, 2026.

Since the rating, $HUMA is down 14.8% after 1 week, down 36.1% after 1 month and down 60.2% to date (from the $1.08 close on Jun 11, 2026).

HUMA Humacyte, Inc.

$0.43 -55.67% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright reiterated its buy rating on Humacyte, Inc. (HUMA) and set a price target of $4.00 on June 11, 2026.
HC Wainwright's $4 price target implies 288.35% upside from Humacyte, Inc.'s ($HUMA) current $1.03 share price.
The stock closed at $0.59 prior to the analyst's call and is currently trading at about $1.03, indicating a more positive outlook from the firm.
Other analysts have varying ratings, with Barclays initiating coverage at Equal-Weight and a target of $0.50, while Benchmark maintains a Speculative Buy rating with a lowered target of $1.00.

Get $HUMA trade alerts by text

We text you when insiders, Congress or big funds trade $HUMA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Humacyte, Inc. alert may contain errors. Disclosures

Analysts Set New Price Targets

On June 11, 2026, HC Wainwright reiterated its buy rating on Humacyte, Inc. (HUMA) with a price target of $4.00. This comes as the stock trades at approximately $1.03 after closing at $0.59. The firm’s decision reflects its positive outlook on the company and its growth potential in the biotech sector.

Comparison with Other Analysts

HC Wainwright’s reaffirmation of its buy rating puts it in contrast with other analysts on Wall Street. For instance, Barclays recently initiated coverage at an Equal-Weight rating with a price target of $0.50, which suggests a more cautious approach. Similarly, Benchmark has maintained a Speculative Buy rating but reduced its target from $2.00 to $1.00 as of August 13, 2026. Additionally, BTIG reiterated a Buy rating with a price target of $2.00 on July 28, 2026, indicating differing levels of optimism about Humacyte's prospects.

Stock Performance Context

Humacyte's stock has seen significant fluctuations, with a 52-week low of $0.53 and a high of $2.55. The recent rally to about $1.03 could reflect renewed investor interest following HC Wainwright's positive rating. The stock is currently trading above its 50-day moving average of $0.64, which may suggest a bullish sentiment among traders.

12-month forecast

$HUMA price target

Humacyte, Inc. daily closes and this analyst's $4 target. Not advice.

What Humacyte, Inc. Does

Humacyte, Inc. is based in Durham, North Carolina, and specializes in developing implantable, bioengineered human tissues. Their innovative approach targets the vascular repair and reconstruction market, aiming to treat various diseases without causing immune rejection. With 184 employees, the company is focused on advancing its technology platform to create human acellular vessels.

Next Steps for Humacyte

Humacyte is scheduled to report its next earnings on November 12, 2026. Investors will be keen to see how its financial performance aligns with analyst expectations and whether the company can maintain momentum from favorable ratings. The backward-looking nature of analyst ratings reminds us that while they provide insight, they reflect past performance and may not fully capture current market dynamics.